Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: The observational Hermine study

Oncologist

Volumn 15, Issue 8, 2010, Pages 799-809

  Extra, Jean Marc ^a   Antoine, Eric C ^b   Vincent Salomon, Anne ^c   Delozier, Thierry ^d   Kerbrat, Pierre ^e   Bethune Volters, Anne ^f   Guastalla, Jean Paul ^g   Spielmann, Marc ^h   Mauriac, Louis ⁱ   Misset, Jean Louis ^j   Serin, Daniel ^k   Campone, Mario ^l   Hebert, Christophe ^m   Remblier, Céline ⁿ   Bergougnoux, Loïc ⁿ   Campana, Frank ⁿ   Namer, Moïse ^o  

^a INSTITUT PAOLI CALMETTES   (France)

^b Clinique Hartmann   (France)

^c INSTITUT CURIE   (France)

^d Centre François Balcesse   (France)

^e CENTRE EUGÈNE MARQUIS   (France)

^f Centre René Hughenin   (France)

^g CENTRE LÉON BÉRARD   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ INSTITUT BERGONIÉ   (France)

^j SAINT LOUIS HOSPITAL   (France)

^k INSTITUT SAINTE CATHERINE   (France)

^l CENTRE RENÉ GAUDUCHEAU   (France)

^m CENTRE ANTOINE LACASSAGNE   (France)

ⁿ Roche   (France)

^o Centre Azureen de Cancerologie   (France)

more..

Author keywords

Human epidermal growth factor receptor 2; Metastatic breast cancer; Overall survival; Trastuzumab; Treatment beyond progression

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CAPECITABINE; DOCETAXEL; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SURVIVAL TIME; TACHYCARDIA; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; OBSERVATION; PHARMACOEPIDEMIOLOGY; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77956793546     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0029     Document Type: Article

References (31)

1. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17: 2639-2648.
2. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369:29-36.
3. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-1684.
4. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23:4265-4274.
5. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
6. Goldhirsch A, Coates AS, Gelber RD et al. First-select the target: Better choice of adjuvant treatments for breast cancer patients. Ann Oncol 2006; 17:1772-1776.
7. ® immunotherapy in metastatic breast cancer. Oncology 2001;61(suppl 2):58-66.
8. ®) therapy in the treatment of metastatic breast cancer. Breast 2004;13:173-183.
9. ® in women with metastatic breast cancer: Results from pivotal clinical studies. Anticancer Drugs 2001; 12(suppl 4):S3-S10.
10. Antoine EC, Extra JM, Vincent-Salomon A et al. Multiple lines of trastuzumab provide a survival benefit for women with metastatic breast cancer: Results from the Hermine cohort study [abstract 2099]. Eur J Cancer 2007; 43(suppl;5):213.
11. Pietras RJ, Pegram MD, Finn RS et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235-2249.
12. Bartsch R, Wenzel C, Hussian D et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study. BMC Cancer 2006;6:63.
13. Fountzilas G, Razis E, Tsavdaridis D et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: A retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer 2003;4:120-125.
14. Gelmon KA, Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories. Clin Breast Cancer 2004;5:52-58; discussion 59-62.
15. Montemurro F, Donadio M, Clavarezza M et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumabbased therapy. The Oncologist 2006;11:318-324.
16. Morabito A, Longo R, Gattuso D et al. Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. Oncol Rep 2006;16:393-398.
17. Stemmler HJ, Kahlert S, Siekiera W et al. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie 2005;28:582-586.
18. Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22:1063-1070.
19. Bartsch R, Wenzel C, Altorjai G et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007;25:3853-3858.
20. García-Sáenz JA, Martín M, Puente J et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 2005;6:325-329.
21. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999-2006.
22. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-543.
23. Shirane M, Fujimoto-Ouchi K, Sekiguchi F et al. Preclinical study of continuous administration of trastuzumab as combination therapy after disease progression with trastuzumab monotherapy [abstract 411]. Eur J Cancer 2005;3(suppl):115.
24. Scaltriti M, Verma C, Guzman M et al. Lapatinib induces HER2 stabilization and enhances the antitumour activity of trastuzumab in vivo [abstract 2559]. Presented at the American Association of Cancer Research Annual Meeting, San Diego, California, April 12-14, 2008.
25. Friess T, Scheuer W, Hasmann M. Combinations of trastuzumab with either pertuzumab or bevacizumab show higher efficacy than lapatinib-based combinations against HER2-positive breast cancer xenografts progressing on trastuzumab monotherapy [poster B102]. Presented at the American Association of Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, California, October 22-26, 2007.
26. O'Shaughnessy J, Blackwell KL, Burstein H et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2 metastatic breast cancer progressing on trastuzumab therapy [abstract 1015]. J Clin Oncol 2008;26(15 suppl):44s.
27. Guarneri V, Lenihan DJ, Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-4115.
28. Pestalozzi BC, Zahrieh D, Price KN et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006;17:935-944.
29. Kirsch DG, Ledezma CJ, Mathews CS et al. Survival after brain metastases from breast cancer in the trastuzumab era [letter]. J Clin Oncol 2005;23: 2114-2116; author reply 2116-2117.
30. Sawrie SM, Meredith RF, Spencer SA et al. Her2-neu status as a predictor of survival in patients with brain metastases from primary breast adenocarcinoma. Poster 1016 presented at the 43rd ASCO Annual Meeting, Chicago, Illinois, USA June 1-5, 2007.
31. Bartsch R, Rottenfusser A, Wenzel C et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 2007;85:311-317.